Matches in Wikidata for { <http://www.wikidata.org/entity/Q92081516> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- Q92081516 description "article scientifique publié en 2020" @default.
- Q92081516 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q92081516 description "scientific article published on 17 April 2020" @default.
- Q92081516 description "wetenschappelijk artikel" @default.
- Q92081516 description "наукова стаття, опублікована 17 квітня 2020" @default.
- Q92081516 name "TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial" @default.
- Q92081516 name "TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial" @default.
- Q92081516 type Item @default.
- Q92081516 label "TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial" @default.
- Q92081516 label "TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial" @default.
- Q92081516 prefLabel "TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial" @default.
- Q92081516 prefLabel "TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial" @default.
- Q92081516 P1433 Q92081516-A62C7EAB-82D3-47A2-A36A-5D1158A1A1E2 @default.
- Q92081516 P1476 Q92081516-057C40AC-B989-4BC1-962C-D972CE4136F5 @default.
- Q92081516 P2093 Q92081516-158731B0-C45C-4E9E-BAAA-57D6E932CE8A @default.
- Q92081516 P2093 Q92081516-3FD1038E-4DD9-4E83-B90D-03662381CED0 @default.
- Q92081516 P2093 Q92081516-69EC4B4B-6D29-4533-AFFB-4D0308FFD256 @default.
- Q92081516 P2093 Q92081516-B9CC2CC9-5F68-424C-8781-C58092770F82 @default.
- Q92081516 P2093 Q92081516-BBC06AC8-1982-4E4E-ACFA-F531A769D15D @default.
- Q92081516 P2093 Q92081516-BF098B0E-F862-48F8-A4F1-EA2B4DF1CD2D @default.
- Q92081516 P2093 Q92081516-C09268AD-F8CB-488A-921A-FCADBABE9489 @default.
- Q92081516 P2093 Q92081516-D5F43A7A-85E6-472B-A941-C8F745123563 @default.
- Q92081516 P2093 Q92081516-E24FDFDA-F682-447A-BE2E-1DE4E6F01114 @default.
- Q92081516 P2093 Q92081516-E4BB3454-5A3D-40BA-9FDE-C214D37E14EF @default.
- Q92081516 P2093 Q92081516-EE1CC71C-EC91-457A-A63B-315451699795 @default.
- Q92081516 P31 Q92081516-3F5EE663-E575-400B-817A-6E9FED70E812 @default.
- Q92081516 P356 Q92081516-1422C052-D800-488A-B68D-DD91DDB56C6C @default.
- Q92081516 P577 Q92081516-0BB55C40-62B9-4A7D-A65F-1A9C82EE90E2 @default.
- Q92081516 P698 Q92081516-66D73670-8067-4B56-8E2D-2DEA3489C3F5 @default.
- Q92081516 P921 Q92081516-5FDA114B-97FE-42CC-A6CC-5C8EF3322D9B @default.
- Q92081516 P921 Q92081516-68B98F07-F62E-45D0-B049-97519D1E8148 @default.
- Q92081516 P921 Q92081516-EF4F98DD-E22C-4F75-A8A1-F524CB2E29C0 @default.
- Q92081516 P356 J.JID.2020.03.962 @default.
- Q92081516 P698 32311398 @default.
- Q92081516 P1433 Q3186921 @default.
- Q92081516 P1476 "TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial" @default.
- Q92081516 P2093 "Christopher Tehlirian" @default.
- Q92081516 P2093 "Dahong Yu" @default.
- Q92081516 P2093 "David M Pariser" @default.
- Q92081516 P2093 "Elena Peeva" @default.
- Q92081516 P2093 "Elizabeth M Kieras" @default.
- Q92081516 P2093 "Jocelyne Papacharalambous" @default.
- Q92081516 P2093 "Michael S Vincent" @default.
- Q92081516 P2093 "Ruolun Qiu" @default.
- Q92081516 P2093 "Seth B Forman" @default.
- Q92081516 P2093 "Steven A Gilbert" @default.
- Q92081516 P2093 "Yves Poulin" @default.
- Q92081516 P31 Q13442814 @default.
- Q92081516 P356 "10.1016/J.JID.2020.03.962" @default.
- Q92081516 P577 "2020-04-17T00:00:00Z" @default.
- Q92081516 P698 "32311398" @default.
- Q92081516 P921 Q10355321 @default.
- Q92081516 P921 Q108853737 @default.
- Q92081516 P921 Q269829 @default.